scholarly journals Inflammatory Markers and Hepcidin are Elevated but Serum Iron is Lower in Obese Women of Reproductive Age

Nutrients ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 217
Author(s):  
Sixtus Aguree ◽  
Manju B. Reddy
Keyword(s):  
Total Cholesterol ◽  
Interleukin 6 ◽  
Inflammatory Markers ◽  
Serum Iron ◽  
Serum Lipids ◽  
Normal Weight ◽  
Obese Women ◽  
C Reactive Protein ◽  
Childbearing Age ◽  
Reactive Protein

Limited evidence suggests that serum iron and hepcidin concentrations are dysregulated in obesity and inflammation. The objective of the present study was to compare C-reactive protein, interleukin-6, circulating levels of hepcidin, serum lipids, and iron status in obese vs. normal-weight women of childbearing age. Healthy women aged 18–30 years were recruited for the study (n = 47: 25 obese and 22 normal weight). Fasting blood samples were obtained to measure serum lipids (total cholesterol, HDL, LDL cholesterol, triglycerides, non-HDL cholesterol), complete blood count, serum iron, total iron-binding capacity, transferrin saturation, serum ferritin, hepcidin, C-reactive protein, and interleukin-6. Obese women had significantly higher mean serum C-reactive protein (p < 0.001), interleukin-6 (p < 0.001), hepcidin (p = 0.024), triglycerides (p < 0.001) and total cholesterol/HDL ratio (p < 0.001) but lower HDL (p = 0.001) and serum iron/hepcidin ratio (p = 0.011) compared with normal-weight women. BMI correlated positively with inflammatory markers, triglycerides, LDL and total cholesterol/HDL ratio, and negatively with HDL and serum iron/hepcidin ratio. Serum iron correlated negatively with ferritin in the obese group (p = 0.030) but positively in normal weight women (p = 0.002). BMI and ferritin were the only predictors of serum iron/hepcidin ratio accounting for 23% of the variation among subjects. Studies are needed to examine anti-inflammatory dietary approaches that can improve iron biomarkers in obese women.

scholarly journals Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: Systematic review and meta-analysis

2021 ◽  
pp. 239698732098400
Author(s):  
JJ McCabe ◽  
E O’Reilly ◽  
S Coveney ◽  
R Collins ◽  
L Healy ◽  
...  
Keyword(s):  
Systematic Review ◽  
Random Effects ◽  
Interleukin 6 ◽  
Inflammatory Markers ◽  
Recurrent Stroke ◽  
Meta Analysis ◽  
Randomised Trials ◽  
C Reactive Protein ◽  
Vascular Events ◽  
Reactive Protein

Background Recent randomised trials showed benefit for anti-inflammatory therapies in coronary disease but excluded stroke. The prognostic value of blood inflammatory markers after stroke is uncertain and guidelines do not recommend their routine measurement for risk stratification. Methods We performed a systematic review and meta-analysis of studies investigating the association of C-reactive protein (CRP), interleukin-6 (IL-6) and fibrinogen and risk of recurrent stroke or major vascular events (MVEs). We searched EMBASE and Ovid Medline until 10/1/19. Random-effects meta-analysis was performed for studies reporting comparable effect measures. Results Of 2,515 reports identified, 39 met eligibility criteria (IL-6, n = 10; CRP, n = 33; fibrinogen, n = 16). An association with recurrent stroke was reported in 12/26 studies (CRP), 2/11 (fibrinogen) and 3/6 (IL-6). On random-effects meta-analysis of comparable studies, CRP was associated with an increased risk of recurrent stroke [pooled hazard ratio (HR) per 1 standard-deviation (SD) increase in loge-CRP (1.14, 95% CI 1.06–1.22, p < 0.01)] and MVEs (pooled HR 1.21, CI 1.10–1.34, p < 0.01). Fibrinogen was also associated with recurrent stroke (HR 1.26, CI 1.07–1.47, p < 0.01) and MVEs (HR 1.31, 95% CI 1.15–1.49, p < 0.01). Trends were identified for IL-6 for recurrent stroke (HR per 1-SD increase 1.17, CI 0.97–1.41, p = 0.10) and MVEs (HR 1.22, CI 0.96–1.55, p = 0.10). Conclusion Despite evidence suggesting an association between inflammatory markers and post-stroke vascular recurrence, substantial methodological heterogeneity was apparent between studies. Individual-patient pooled analysis and standardisation of methods are needed to determine the prognostic role of blood inflammatory markers and to improve patient selection for randomised trials of inflammatory therapies.

Baseline high-sensitivity C-reactive protein to predict progression-free survival in metastatic renal cell carcinoma patients treated with first-line sunitinib.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15527-e15527
Author(s):  
Ryuichi Mizuno ◽  
Go Kimura ◽  
Tsunenori Kondo ◽  
Takeshi Ueda ◽  
Hidehiko Hara ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
Inflammatory Markers ◽  
Progression Free Survival ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
First Line ◽  
Free Survival ◽  
Reactive Protein ◽  
Hs Crp ◽  
Serum Inflammatory Markers

e15527 Background: Predicting the efficacy of tyrosine kinase inhibitors (TKI) would be of clinical value in patients with metastatic renal cell carcinoma (mRCC). We tested the hypothesis that serum inflammatory markers are associated with clinical outcome in mRCC patients at favorable or intermediate prognostic risk treated with first-line sunitinib. Methods: Eighty-nine mRCC patients were prospectively monitored at baseline (day 0) during sunitinib treatment. Serum interleukin-6 and 8 levels were determined by CLEIA and ELISA, respectively. A high-sensitivity C-reactive protein (hs-CRP) levels were measured using laser nephelometry. Correlations between baseline interleukin-6, 8, hs-CRP levels and response to sunitinib, and progression-free survival (PFS) were examined. Results: Median PFS was 9.2 months. Clinical benefit rate (CBR; percent complete responses+partial responses +stable disease 24 weeks) was 57.3%. Baseline interleukin-8 (P=0.0240) and hs-CRP (P=0.0060) was associated with CBR. No association between baseline interleukin-6 and 8 with PFS was observed. However, baseline hs-CRP were associated with PFS (P=0.0016; unit risk 1.010; 95% CI 1.004 to 1.017). Conclusions: Baseline serum inflammatory markers could be of clinical interest in sunitinib-treated mRCC patiens to predict outcome. Baseline hs-CRP serum levels warrant further study. Clinical trial information: UMIN000009622.

scholarly journals Plasma Volume Is an Important Determinant in Assessing Metabolic and Iron Biomarkers in Young Women

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 94-94
Author(s):  
Sixtus Aguree ◽  
Manju Reddy
Keyword(s):  
Plasma Volume ◽  
Serum Iron ◽  
Serum Lipids ◽  
Binding Capacity ◽  
Venous Blood ◽  
Transferrin Saturation ◽  
Normal Weight ◽  
Obese Women ◽  
Funding Sources ◽  
Adjustment Factors

Abstract Objectives Plasma volume (PV) variations among individuals can affect the concentration of blood biomarkers but this is not often evaluated in assessing nutritional status. We aimed to assess the association between estimated PV, metabolic and iron biomarkers in young obese and normal weight women. Methods Healthy women aged 18–30 y were recruited for the study (n = 47: 25 obese and 22 normal weight). Fasting venous blood samples were obtained to measure serum lipids, comprehensive metabolic panel, iron biomarkers (serum iron, total iron binding capacity, transferrin saturation (%TS), hemoglobin, ferritin and, hepcidin). PV was estimated using Kaplan-Hakim formula: PV = (1-hematocrit) × [a + (b × weight in kg)] where adjustment factors were a = 864, and b = 47.9. Associations between PV and other biomarkers were assessed using Pearson's correlation. Results As expected, PV was higher in obese (3482 (545) mL) than normal weight women (2268 (250) mL). When all subjects were combined PV was negatively correlated with HDL (r = −0.49, P = 0.001), creatinine (r = −0.48, P = 0.001), sodium (r = −0.31, P = 0.034), calcium (r = −0.30, P = 0.044), albumin (r = −0.46, P = 0.001), serum iron (r = −0.34, P = 0.022), and %TS (r = −0.31, P = 0.036) but positively correlated with triglycerides (r = 0.40, P = 0.005), cholesterol/HDLC ratio(r = 0.55, P &lt; 0.001). In normal weight women, PV was not correlated with any of these biomarkers. However, in obese women, there was a strong correlation of PV with creatinine (r = −0.61, P = 0.001), calcium (r = −0.50, P = 0.012), and albumin (r = −0.43, P = 0.030). Conclusions Our results suggest that differences in PV may account for some variations in serum lipids, creatinine, sodium, calcium, albumin, and iron biomarker concentrations in women. This implies that different cutoffs may be needed for defining deficiencies in obesity after correcting for plasma volume. Funding Sources Doris A. Adams Endowed Chair funds at Iowa State University.

scholarly journals The Role of C-reactive Protein and Interleukin 6 in the Cases of Preeclampsia Associated with Obesity

2019 ◽  
Vol 70 (3) ◽  
pp. 805-808 ◽  
Author(s):  
Izabella Petre ◽  
Marius Craina ◽  
Nicolae Suciu ◽  
Alina Sisu ◽  
Radu Dumitru Moleriu ◽  
...  
Keyword(s):  
Risk Factor ◽  
Early Detection ◽  
Pregnant Women ◽  
Interleukin 6 ◽  
Inflammatory Markers ◽  
Inflammatory Condition ◽  
European Level ◽  
C Reactive Protein ◽  
Reactive Protein

In the management of preeclampsia/eclampsia, it would be useful at least at European level, to have clear protocols for early detection and approach of cases with hypertension, as well as to create an algorithm to identify the predisposition to hypertensive pregnancy pathology. The aim has been to identify the favorable factors and the evolution of the pregnancy in the 100 patients admitted to the obstetrics clinic between January 2014 and December 2018, aged between 15-44 years, who have been diagnosed with preeclampsia. In recent years, the management of pregnant women with preeclampsia has improved a lot due to a better understanding of the pathogenesis and a refinement of adequate pregnancy monitoring. Obesity has been shown to be a risk factor in preeclampsia. Several studies have identified preeclampsia as an inflammatory condition. A large number of inflammatory markers, such as C-reactive protein (PCR) and Interleukin 6 (IL-6), have been shown to be elevated in pregnant women with preeclampsia.

505 INTERLEUKIN-6, C-REACTIVE PROTEIN, FIBRINOGEN, AND RISK OF RECURRENCE AFTER ISCHEMIC STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS

2021 ◽  
Vol 50 (Supplement_2) ◽  
pp. ii1-ii4
Author(s):  
J J McCabe ◽  
E O’Reilly ◽  
S Coveney ◽  
J Harbison ◽  
R Collins ◽  
...  
Keyword(s):  
Systematic Review ◽  
Random Effects ◽  
Interleukin 6 ◽  
Inflammatory Markers ◽  
Recurrent Stroke ◽  
Meta Analysis ◽  
Randomised Trials ◽  
C Reactive Protein ◽  
Vascular Events ◽  
Reactive Protein

Abstract Background Recent randomised trials showed benefit for anti-inflammatory therapies in coronary disease but excluded stroke. The prognostic value of blood inflammatory markers after stroke is uncertain and guidelines do not recommend their routine measurement for risk stratification. Methods We performed a systematic review and meta-analysis of studies investigating the association of C-reactive protein (CRP), interleukin-6 (IL-6) and fibrinogen and risk of recurrent stroke or major vascular events (MVEs). We searched EMBASE and Ovid Medline until 10/1/19. Random-effects meta-analysis was performed for studies reporting comparable effect measures. Results Of 2,515 reports identified, 39 met eligibility criteria (IL-6, n = 10; CRP, n = 33; fibrinogen, n = 16). An association with recurrent stroke was reported in 12/26 studies (CRP), 2/11 (fibrinogen) and 3/6 (IL-6). On random-effects meta-analysis of comparable studies, CRP was associated with an increased risk of recurrent stroke [pooled hazard ratio (HR) per 1 standard-deviation (SD) increase in loge-CRP (1.14, 95% CI 1.06-1.22, p &lt; 0.01)] and MVEs (pooled HR 1.21, CI 1.10-1.34, p &lt; 0.01). Fibrinogen was also associated with recurrent stroke (HR 1.26, CI 1.07-1.47, p &lt; 0.01) and MVEs (HR 1.31, 95% CI 1.15-1.49, p &lt; 0.01). Trends were identified for IL-6 for recurrent stroke (HR per 1-SD increase 1.17, CI 0.97-1.41, p = 0.10) and MVEs (HR 1.22, CI 0.96-1.55, p = 0.10). Conclusion Despite evidence suggesting an association between inflammatory markers and post-stroke vascular recurrence, substantial methodological heterogeneity was apparent between studies. Individual-patient pooled analysis and standardisation of methods are needed to determine the prognostic role of blood inflammatory markers and to improve patient selection for randomised trials of inflammatory therapies.

The role of inflammatory biomarkers in CHD-associated pulmonary hypertension in children

2016 ◽  
Vol 27 (2) ◽  
pp. 255-260 ◽  
Author(s):  
Gokcen Oz-Tuncer ◽  
Rana Olgunturk ◽  
Ayhan Pektas ◽  
Erman Cilsal ◽  
Serdar Kula ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Ejection Fraction ◽  
Interleukin 6 ◽  
Inflammatory Markers ◽  
Healthy Children ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Hypertension In Children ◽  
Fractional Shortening

AbstractObjectiveThe present study aims to identify the role of inflammatory markers such as C-reactive protein, interleukin-6, and fractalkine in CHD-associated pulmonary hypertension in children.MethodsThis is a prospective review of 37 children with CHD-related pulmonary hypertension, 21 children with congenital heart defects, and 22 healthy children.ResultsSerum C-reactive protein and interleukin-6 levels were significantly higher in the children with CHD-related pulmonary hypertension (respectively, p=0.049 and 0.026). Serum C-reactive protein concentrations correlated negatively with ejection fraction (r=−0.609, p=0.001) and fractional shortening (r=−0.452, p=0.007) in the pulmonary hypertension group. Serum fractalkine concentrations correlated negatively with ejection fraction (r=−0.522, p=0.002) and fractional shortening (r=−0.395, p=0.021) in the children with pulmonary hypertension. Serum interleukin-6 concentrations also correlated negatively with Qs (r=−0.572, p=0.021), positively with Rs (r=0.774, p=0.001), and positively with pulmonary wedge pressure (r=0.796, p=0.006) in the pulmonary hypertension group. A cut-off value of 2.2 IU/L for C-reactive protein was able to predict pulmonary hypertension with 77.5% sensitivity and 77.5% specificity. When the cut-off point for interleukin-6 concentration was 57.5 pg/ml, pulmonary hypertension could be predicted with 80% sensitivity and 75% specificity.ConclusionInflammation is associated with the pathophysiology of pulmonary hypertension. The inflammatory markers C-reactive protein and interleukin-6 may have a role in the clinical evaluation of paediatric pulmonary hypertension related to CHDs.

scholarly journals Adherence to cancer prevention recommendations and antioxidant and inflammatory status in premenopausal women

2015 ◽  
Vol 114 (1) ◽  
pp. 134-143 ◽  
Author(s):  
Yukiko Morimoto ◽  
Fanchon Beckford ◽  
Robert V. Cooney ◽  
Adrian A. Franke ◽  
Gertraud Maskarinec
Keyword(s):  
Cancer Research ◽  
Cancer Prevention ◽  
Statistical Significance ◽  
Premenopausal Women ◽  
Normal Weight ◽  
Obese Women ◽  
C Reactive Protein ◽  
Processed Meats ◽  
Reactive Protein ◽  
Inflammatory Status

For cancer prevention, the World Cancer Research Fund and American Institute for Cancer Research (WCRF/AICR) emphasise recommendations to improve individual behaviour, including avoidance of tobacco products, maintaining a lean body mass, participating in physical activity, consuming a plant-based diet, and minimising the consumption of energy-dense foods, such as sodas, red and processed meats and alcohol. In the present study of 275 healthy premenopausal women, we explored the association of adherence scores with levels of three biomarkers of antioxidant and inflammation status: serum C-reactive protein (CRP), serum γ-tocopherol and urinary F2-isoprostane. The statistical analysis applied linear regression across categories of adherence to WCRF/AICR recommendations. Overall, seventy-two women were classified as low ( ≤ 4), 150 as moderate (5–6), and fifty-three as high adherers ( ≥ 7). The unadjusted means for CRP were 2·7, 2·0 and 1·7 mg/l for low, moderate and high adherers (Ptrend= 0·03); this association was strengthened after adjustment for confounders (Ptrend= 0·006). The respective values for serum γ-tocopherol were 1·97, 1·63 and 1·45 μg/ml (Ptrend= 0·02 before and Ptrend= 0·03 after adjustment). Only for urinary F2-isoprostane, the lower values in high adherers (16·0, 14·5, and 13·3 ng/ml) did not reach statistical significance (Ptrend= 0·18). In an analysis by BMI, overweight and obese women had higher biomarker levels than normal weight women; the trend was significant for CRP (Ptrend< 0·001) and γ-tocopherol (Ptrend= 0·003) but not for F2-isoprostane (Ptrend= 0·14). These findings suggest that both adherence to the WCRF/AICR guidelines and normal BMI status are associated with lower levels of biomarkers that indicate oxidative stress and inflammation.

Sign in / Sign up

Export Citation Format

Share Document